ReviewCytokine2015
Beyond Candida albicans: Mechanisms of immunity to non-albicans Candida species.
Review in Cytokine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- Preventive action of ketamine alone and in combination with antifungals on Candida biofilm formation in catheters.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Closing the Gap: Advances and Barriers onInternational journal of molecular sciences · 2026Review
- Oral Candida colonization and virulence in children with orofacial clefts: a cross-sectional study.BMC oral health · 2026Article
- Evaluation of immunological and gene expression responses induced by Galectin-3 and whole-sonicatedOpen veterinary journal · 2026Article
- Drug susceptibility ofIranian journal of microbiology · 2026Article
- Anticandidal Activity of Lipopeptides Containing an LL-37-Derived Peptide Fragment KR12.Molecules (Basel, Switzerland) · 2025Article
- Comparative Evaluation ofBiomedicines · 2024Article
- Molecular cloning, expression, and purification, along withFrontiers in fungal biology · 2024Article
- A gut-oral microbiome-driven axis controls oropharyngeal candidiasis through retinoic acid.JCI insight · 2022Article
- The Role of B-Cells and Antibodies againstVaccines · 2021Review
- A new humanized antibody is effective against pathogenic fungi in vitro.Scientific reports · 2021Article
- Vaccination with Secreted Aspartyl Proteinase 2 Protein fromInfection and immunity · 2020Article
- Candida albicans enhances meropenem tolerance of Pseudomonas aeruginosa in a dual-species biofilm.The Journal of antimicrobial chemotherapy · 2020Article
- The role of Lactobacillus species in the control of Candida via biotrophic interactions.Microbial cell (Graz, Austria) · 2019Review
- Article
- The critical role of Dectin-1 in host controlling systemicAmerican journal of translational research · 2019Article
- The Role of IL-17 in Protection against Mucosal Candida Infections.Journal of fungi (Basel, Switzerland) · 2017Review
- A chronic hemodialysis patient with isolated pulmonary valve infective endocarditis caused by non-albicans Candida: a rare case and literature review.BMC nephrology · 2017Review
- New Benzimidazole-1,2,4-Triazole Hybrid Compounds: Synthesis, Anticandidal Activity and Cytotoxicity Evaluation.Molecules (Basel, Switzerland) · 2017Article
- Lactoferrin, chitosan and Melaleuca alternifolia-natural products that show promise in candidiasis treatment.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The fungal genus Candida encompasses numerous species that inhabit a variety of hosts, either as commensal microbes and/or pathogens. Candida species are a major cause of fungal infections, yet to date there are no vaccines against Candida or indeed any other fungal pathogen. Our knowledge of immunity to Candida mainly comes from studies on Candida albicans, the most frequent species associated with disease. However, non-albicans Candida (NAC) species also cause disease and their prevalence is increasing. Although research into immunity to NAC species is still at an early stage, it is becoming apparent that immunity to C. albicans differs in important ways from non-albicans species, with important implications for treatment, therapy and predicted demographic susceptibility. This review will discuss the current understanding of immunity to NAC species in the context of immunity to C. albicans, and highlight as-yet unanswered questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.